Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for Apnea returned no results
Showing 46 to 60 of 69 results for apnoea

  1. Thoracoscopic aortopexy for severe primary tracheomalacia (IPG243)

    Evidence-based recommendations on thoracoscopic aortopexy for severe primary tracheomalacia. This involves attaching the aorta to the sternum with sutures, using special instruments through small cuts in the chest (keyhole surgery).

    Interventional procedures guidance
    Published
    12 December 2007
    View recommendations

    Sections for IPG243

  2. Auto- versus fixed-level CPAP for OSAHS: What is the clinical and cost effectiveness of auto- and fixed-level continuous positive airway pressure (CPAP) for managing mild obstructive sleep apnoea/hypopnoea syndrome (OSAHS)?

    continuous positive airway pressure (CPAP) for managing mild obstructive sleep apnoea/hypopnoea syndrome (OSAHS)? Any explanatory...

    Research recommendation
    Published
    30 September 2021

  3. Neonatal infection: antibiotics for prevention and treatment (NG195)

    This guideline covers preventing bacterial infection in healthy babies of up to and including 28 days corrected gestational age, treating pregnant women whose unborn baby is at risk of infection, and caring for babies of up to and including 28 days corrected gestational age with a suspected or confirmed bacterial infection. It aims to reduce delays in recognising and treating infection and prevent unnecessary use of antibiotics. The guideline does not cover viral infections.

    NICE guideline
    Last updated
    19 March 2024
    View recommendations

    Sections for NG195

  4. The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs (MIB159)

    NICE has developed a medtech innovation briefing (MIB) on The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs .

    Medtech innovation briefing
    Published
    14 September 2018

  5. Cerebral palsy in under 25s: assessment and management (NG62)

    This guideline covers diagnosing, assessing and managing cerebral palsy in children and young people from birth up to their 25th birthday. It aims to make sure they get the care and treatment they need for the developmental and clinical comorbidities associated with cerebral palsy, so that they can be as active and independent as possible.

    NICE guideline
    Published
    25 January 2017
    View recommendations

    Sections for NG62

  6. NICE describes how weight loss drug tirzepatide will be rolled out

    The medication will initially be offered only to those people with the highest clinical needs.

    News
    Last updated
    6 December 2024

  7. In moderate OSAHS, which clinical and physiological phenotypes predict treatment response to customised mandibular advancement splints?

    Source guidance details Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s

    Research recommendation
    Published
    30 September 2021

  8. Mandibular advancement splints for severe OSAHS: What is the clinical and cost effectiveness of mandibular advancement splints for managing severe OSAHS?

    Source guidance details Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s

    Research recommendation
    Published
    30 September 2021

  9. Oxygen therapy for OSAHS: What is the clinical and cost effectiveness of nocturnal oxygen compared with placebo in people with OSAHS who are unable to tolerate CPAP?

    Source guidance details Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s

    Research recommendation
    Published
    30 September 2021

  10. Mandibular advancement splints for mild symptomatic OSAHS and moderate OSAHS: In mild symptomatic OSAHS, which clinical and physiological phenotypes predict treatment response to customised mandibular advancement splints?

    Source guidance details Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s

    Research recommendation
    Published
    30 September 2021

  11. Treatment for people with COPD–OSAHS overlap syndrome: What is the optimal treatment for people with COPD–OSAHS overlap syndrome: non-invasive ventilation or CPAP?

    Source guidance details Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s

    Research recommendation
    Published
    30 September 2021

  12. Upper airway surgery in people unable to tolerate or adhere to CPAP: What is the clinical and cost effectiveness of upper airway surgical interventions for people with OSAHS who are unable to tolerate or adhere to CPAP?

    Source guidance details Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s

    Research recommendation
    Published
    30 September 2021

  13. What is the clinical and cost effectiveness of auto- and fixed-level continuous positive airway pressure (CPAP) for managing moderate and severe OSAHS?

    Source guidance details Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s

    Research recommendation
    Published
    30 September 2021

  14. Interventions to improve CPAP adherence: Which interventions, including behavioural interventions, are most clinically and cost effective to improve adherence to CPAP in people with OSAHS, obesity hypoventilation syndrome (OHS) and COPD–OSAHS (chronic obstructive pulmonary disease–OSAHS) overlap syndrome who have difficulty using CPAP?

    Source guidance details Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s

    Research recommendation
    Published
    30 September 2021

  15. Daridorexant for treating long-term insomnia (TA922)

    Evidence-based recommendations on daridorexant (QUVIVIQ) for treating long-term insomnia in adults.

    Technology appraisal guidance
    Published
    18 October 2023
    View recommendations

    Sections for TA922